Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Megestrol melanoma study

L Nathanson, M Garrison

    World Journal of Surgery
    |May 1, 1995
    PubMed
    Summary
    This summary is machine-generated.

    Adding megestrol acetate to chemotherapy for metastatic melanoma significantly improved response rates and survival. This combination therapy showed tolerable toxicity and potential for weight gain in patients with viscerally dominant disease.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Cholinergic Stimulation by Pyridostigmine Bromide Before Myocardial Infarction Prevent Cardiac and Autonomic Dysfunction.

    Scientific reports·2019
    Same author

    Copy number variation in pediatric multiple sclerosis.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2012
    Same author

    Ossification of auricles of external ears associated with acromegaly.

    Radiology·2010
    Same author

    The genetics of schizophrenia.

    Journal of abnormal psychology·2010
    Same author

    Laparoscopic distal pancreatectomy: the Brisbane experience of forty-six cases.

    HPB : the official journal of the International Hepato Pancreato Biliary Association·2008
    Same author

    Hypercalcemia mediated by parathyroid hormone-related protein as an early manifestation of pancreatic adenocarcinoma metastasis: a case report.

    American journal of clinical oncology·2001
    Same journal

    Prediction Models for Sentinel Lymph Node Metastasis in Clinically Node-Negative Breast Cancer: Validation of Existing Nomograms, Model Development, and Ensemble Evaluation.

    World journal of surgery·2026
    Same journal

    Indicators for Monitoring Recovery From Surgery to Discharge Using Accelerometer in Patients With Esophageal Cancer.

    World journal of surgery·2026
    Same journal

    The Safety of In-Hospital Delay and the Utility of dNLR in Elderly Patients With Acute Appendicitis.

    World journal of surgery·2026
    Same journal

    Feasibility of Post-Operative Telehealth for Pediatric Surgical Patients in Malawi-A Mixed Methods Analysis.

    World journal of surgery·2026
    Same journal

    Surgical Infrastructure and Workforce Readiness in Rwanda's District and Level 2 Teaching Hospitals: A Nationwide Facility-Based Survey.

    World journal of surgery·2026
    Same journal

    From General Preparedness to Injury-Pattern-Specific Trauma Resource Planning.

    World journal of surgery·2026
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Metastatic melanoma with visceral involvement presents a significant treatment challenge.
    • Standard chemotherapy regimens have shown limited efficacy in improving long-term survival for such patients.

    Purpose of the Study:

    • To evaluate the efficacy and safety of adding megestrol acetate to a dacarbazine, cisplatin, and carmustine chemotherapy regimen for metastatic melanoma.
    • To assess the impact on objective response rate, duration of response, and overall survival.

    Main Methods:

    • A cohort of 22 patients with metastatic melanoma received chemotherapy (dacarbazine, cisplatin, carmustine) combined with megestrol acetate.
    • Dosing details included megestrol acetate (160 mg/day PO), dacarbazine (220 mg/m2/day IV for 3 days), cisplatin (25-30 mg/m2/day IV for 3 days) every 3 weeks, and carmustine (150 mg/m2 IV single dose) every 6 weeks.

    Related Experiment Videos

  • Toxicity, dosing adherence, weight changes, objective response rate, duration of response, and survival were monitored.

    • Main Results:

    • An objective response rate of 56% was observed, including responses in visceral sites.
    • The median duration of response was 37.5+ weeks.
    • A median survival of 15 months was achieved, exceeding that of most prior studies.
    • Toxicity was tolerable, with over 80% of ideal dosing achieved in the first two cycles.
    • A mean weight gain of 0.95 kg was noted.

    Conclusions:

    • Megestrol acetate, when combined with dacarbazine, carmustine, and cisplatin chemotherapy, may enhance objective response rates and prolong median survival in patients with viscerally dominant metastatic melanoma.
    • The combination therapy demonstrated tolerable toxicity and potential for weight gain.